The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis

ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis

February 1, 2013 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON, D.C.—In 2011, rituximab was approved by the U.S. Food and Drug Administration for treatment in adults for two forms of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis—granulomatosis with polyangiitis (GPA; Wegener’s) and microscopic polyangiitis (MPA)—based on the results of the Rituximab for ANCA-Associated Vasculitis (RAVE) trial.1 Prior to rituximab, cyclophosphamide was used for many years as off-label treatment of these diseases and remains a viable option for a select group of patients, according to Carol Langford, MD, director of the Center for Vasculitis Care and Research at the Cleveland Clinic.

You Might Also Like
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab
  • ACR/ARHP Annual Meeting 2012: Physicians Find Treatment Options Limited for Scleroderma Bowel Disease
  • Rituximab Use Increasing in Treatment of Pediatric Vasculitis
Explore This Issue
February 2013
Also By This Author
  • Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus

“We now have two effective options for remission induction of severe GPA/MPA, and that is great news for us and most importantly for our patients,” said Dr. Langford here at the 2012 ACR/ARHP Annual Meeting, held November 9–14. [Editor’s Note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Billed as “The Great Debate,” the session was a history lesson on the one hand, with Dr. Langford discussing the long years of experience, both personal and published, with cyclophosphamide; and, on the other hand, an overview of the current evidence establishing the role of rituximab as first-line therapy for remission induction in patients with severe disease by Ulrich Specks, MD, professor of medicine in the division of pulmonary and critical care medicine at the Mayo Clinic, Rochester, Minn.

Treatment Consensus on Some Patients

What emerged was an agreement that rituximab is the drug of choice in patients with severe disease relapse, as well as for those who have received prior treatment with cyclophosphamide.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For other select patients, however, cyclophosphamide may still play an important role. Both Drs. Langford and Specks agreed that patients who were excluded from the RAVE trial should not automatically be considered for rituximab. Patients excluded from RAVE included those with limited disease, those with disease that was too severe as demonstrated by a serum creatinine greater than 4.0 mg/dL, or the need for mechanical ventilation because of alveolar hemorrhage.

“Data from the RAVE trial cannot necessarily be extrapolated to patients that are substantially different from the trial cohort,” said Dr. Specks, adding that evidence to justify the use of rituximab, as well as cyclophosphamide, for patients with ANCA-associated vasculitis in patient populations different from the RAVE cohort needs to come from sources other than the RAVE trial.

One such source, he said, is from the Rituximab Versus Cyclophosphamide in ANCA-Associated Vasculitis (RITUXVAS) trial, which included patient populations that were different, but what he sees as complementary, to the RAVE trial.2 The patients in the RITUXVAS trial all had newly diagnosed ANCA-positive disease and severe renal disease (more severe than in the RAVE trial). The RITUXVAS trial found no difference in sustained remission at 12 months between rituximab plus cyclophosphamide versus cyclophosphamide followed by oral azathiprine.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates, Vasculitis Tagged With: ANCA-Associated Vasculitis, cyclophosphamide, rituximab, TreatmentIssue: February 2013

You Might Also Like:
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab
  • ACR/ARHP Annual Meeting 2012: Physicians Find Treatment Options Limited for Scleroderma Bowel Disease
  • Rituximab Use Increasing in Treatment of Pediatric Vasculitis
  • ACR/ARHP Annual Scientific Meeting Plenary Highlights Targets and Treatments for Several Diseases

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)